No abstract available
Keywords:
alpha-synuclein; biomarkers; brain cell type-specific; neurological disorder; personalized medicine; protein synthesis; proteomics; synaptic.
Grants and funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Authors acknowledge support by Institutional Funds of Morehouse School of Medicine and NIH/NINDS U54NS060659 to Neuroscience Institute, Morehouse School of Medicine.